Trial Title:
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
NCT ID:
NCT05912075
Condition:
Locally-advanced Rectal Cancer
Conditions: Official terms:
Rectal Neoplasms
Capecitabine
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
Comparative phase 1b trial with randomization
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
mFOLFIRINOX
Description:
prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
Arm group label:
LCRT
Intervention type:
Radiation
Intervention name:
Pelvic radiotherapy LCRT
Description:
50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday)
for 5 weeks
Arm group label:
LCRT
Intervention type:
Drug
Intervention name:
Capecitabine
Description:
800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given
concomitantly during the 5 weeks of radiotherapy
Arm group label:
LCRT
Intervention type:
Drug
Intervention name:
TOLINAPANT (ASTX660)
Description:
starting from 14 days before the first dose of radiotherapy, for 10 weeks.
Arm group label:
LCRT
Arm group label:
SCRT
Intervention type:
Radiation
Intervention name:
Pelvic radiotherapy SCRT
Description:
total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
Arm group label:
SCRT
Intervention type:
Drug
Intervention name:
FOLFOX4
Description:
given every 2 weeks for 9 cycles, starting 10 days after the last session of short course
radiotherapy
Arm group label:
SCRT
Intervention type:
Drug
Intervention name:
CAPOX
Description:
every 3 weeks for 6 cycles, starting 10 days after the last session of short course
radiotherapy.
Arm group label:
SCRT
Other name:
Capecitabine + Oxaliplatine
Summary:
Compare two arms:
- Chemotherapy followed by tolinapant (ASTX660) in combination with Long-Course Radio
Chemotherapy (LCRT), and
- Tolinapant (ASTX660) in combination with Short-Course Radiotherapy (SCRT) followed
by chemotherapy For each patient, the treatment arm will be allocated on the
following basis: patients will be allocated to the chemotherapy followed by LCRT arm
unless they present at least one of the following criteria: contraindication to
receive mFOLFIRINOX (including intolerance to irinotecan and UGT1A1*28
polymorphism), age > 75, general condition incompatible with the radiotherapy
schedule of LCRT. In such case, patients will be allocated to the SCRT arm.
Tolinapant (ASTX660) will be administered orally once a day for 7 consecutive days every
other week during 10 weeks (One week On / One week Off during 10 weeks).
Both treatment arms will have a dose escalation part to determine the MTD and/or RP2D,
followed by an expansion part where up to 21 subjects will be dosed at the RP2D. Both
arms will enroll simultaneously.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Locally advanced rectum cancer where primary resection without chemoradiotherapy is
unlikely to achieve clear margins as defined by:
- a distance between the tumor or its lymph node and the mesorectal fascia ≤ 2 mm on
the pelvic MRI at diagnosis.
- *and/or N2
- No evidence of metastatic disease on CT-scan (chest and abdomen), including
resectable metastases
- Age : ≥ 18 years old at the time of informed consent
- Successfully received at least 4 cycles and up to 6 cycles of mFOLFIRINOX (LCRT arm
only)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0 or 1
- Acceptable organ functions, as evidenced by the following laboratory data:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0×upper
limit of normal (ULN)
- Total serum bilirubin ≤1.5×ULN
- Absolute neutrophil count (ANC): ≥2,000 cells/mm^3
- Platelet count: ≥100,000 cells/mm^3
- Hemoglobin: ≥ 9.0 g/dL
- Serum creatinine levels ≤1.5×ULN, or calculated (by Cockcroft-Gault formula or
other accepted formula) or measured creatinine clearance ≥50 mL/min
- Amylase and lipase ≤1.5xULN
- Adequate blood coagulation function as evidenced by an International Normalized
Ratio (INR) ≤ 1.5.
- Women of childbearing potential must have a negative serum β-HCG pregnancy test
within 3 days prior to the administration of the first study treatment and/or urine
pregnancy 12 hours prior to the administration of the first study treatment.
- Female subjects of childbearing potential should be willing to use a highly
effective method of contraception or be surgically sterile, or abstain from
heterosexual activity for the course of the study through 6 months after the last
dose of study medication. Subjects of childbearing potential are those who have not
been surgically sterilized or have not been free from menses for > 1 year.
- Male subjects should agree to use an adequate method of contraception starting
with the first dose of study therapy through 6 months after the last dose of
study therapy.
- Also, it is recommended that women of childbearing potential partner use a
highly effective method of contraception.
- Patient should understand, sign, and date the written informed consent form prior to
any protocol-specific procedures performed. Patient must be able and willing to
comply with study visits and procedures as per protocol.
- Patient must be affiliated to a social security system or beneficiary of the same.
Exclusion Criteria:
- Any contraindications to MRI (e.g. subjects with pacemakers, claustrophobia,
excessive weight, etc).
- Participation in another clinical study with an investigational product during the
last 3 months.
- No other anticancer therapy during study participation. (however, informed consent
can be signed during mFOLFIRINOX for patients willing to enter the LCRT arm).
- Hypersensitivity to tolinapant (ASTX660) or excipients of the drug product, or to
any other component of the study treatment regimen, including:
- 5-FU, capecitabine and known dihydropyrimidine dehydrogenase (DPD) deficiency,
or
- Oxaliplatin, or
- Irinotecan and known Gilbert disease or genotype UGT1A1 (LCRT arm only)
- Previous radiotherapy in the pelvic region
- Preexisting condition that would deter radiotherapy, e.g. fistulas, severe
ulcerative colitis (including subjects currently taking sulphasalazine), active
Crohn's disease, prior adhesions
- Preexisting condition that would deter chemotherapy, e.g. pneumonitis, pulmonary
fibrosis, pernicious anemia or other anemias caused by vitamin B12 deficiency
- Prior rectal surgery
- Prior investigational treatment for rectal cancer
- Poor medical risk because of systemic diseases (e.g., uncontrolled infections,
uncontrolled diabetes) in addition to the qualifying disease under study
- Life-threatening illness, significant organ system dysfunction, or other condition
that, in the investigator's opinion, could compromise subject safety or the
integrity of the study outcomes, or interfere with the absorption or metabolism of
tolinapant (ASTX660)
- A history of, or at risk for, cardiac disease, as evidenced by 1 or more of the
following conditions:
- Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram
(ECHO) or multiple-gated acquisition scan (MUGA)
- Congestive cardiac failure of ≥ Grade 3 severity according to New York Heart
Association (NYHA) functional classification defined as subjects with marked
limitation of activity and who are comfortable only at rest
- Unstable cardiac disease including unstable angina or hypertension as defined
by the need for overnight hospital admission within the last 3 months (90 days)
- History or presence of complete left bundle branch block, third-degree heart
block, cardiac pacemaker, or clinically significant arrhythmia
- Concurrent treatment with any medication that prolongs QT interval and may
induce torsades de pointes and which cannot be discontinued at least 2 weeks
before treatment with tolinapant (ASTX660)
- Personal history of long QTc syndrome or ventricular arrhythmias including
ventricular bigeminy
- Screening 12-lead ECG with measurable QTc interval (according to either
Fridericia's or Bazett's correction) of ≥470 msec)
- Any other condition that, in the opinion of the investigator, could put the
subject at increased cardiac risk
- Refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory
bowel disease and/or bowel obstruction), or significant bowel resection that may
impair adequate absorption and bioavailability of study drug. Major disturbance of
bowel function (e.g. gross fecal incontinence or requiring > 6 mg loperamide each
day).
- Known history of human immunodeficiency virus (HIV) infection; or seropositive
results consistent with active hepatitis B virus (HBV) or active hepatitis C virus
(HCV) infection.
- Peripheral sensory neuropathy grade >2
- Pregnancy or ongoing breastfeeding
- Patient under guardianship or deprived of his liberty by a judicial or
administrative decision or incapable of giving its consent.
Yellow fever vaccine and live attenuated vaccines are contraindicated due to risk of
severe vaccine-induced infection.
NB :
- The currently authorized COVID-19 vaccines are not live vaccines and therefore can
be safely administered.
- For patients registered in LCRT, all eligibility criteria will be fulfilled during
mFOLFIRINOX (until 2 weeks after the end of mFOLFIRINOX).
- For patients registered in SCRT, all eligibility criteria will be fulfilled before
any treatment.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Centre Léon Bérard
Address:
City:
Lyon
Zip:
69373
Country:
France
Status:
Not yet recruiting
Contact:
Last name:
Jessica SERRAND, MD
Email:
Jessica.SERRAND@lyon.unicancer.fr
Contact backup:
Last name:
Alexandra LAURET
Email:
Alexandra.LAURET@lyon.unicancer.fr
Facility:
Name:
Gustave Roussy
Address:
City:
Villejuif
Zip:
94805
Country:
France
Status:
Recruiting
Contact:
Last name:
Eric DEUTSCH, Md, PhD
Email:
Eric.DEUTSCH@gustaveroussy.fr
Contact backup:
Last name:
Catherine RICHON
Email:
catherine.richon@gustaveroussy.fr
Start date:
December 19, 2023
Completion date:
January 2029
Lead sponsor:
Agency:
Gustave Roussy, Cancer Campus, Grand Paris
Agency class:
Other
Source:
Gustave Roussy, Cancer Campus, Grand Paris
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05912075
